OneThree Biotech
OneThree Biotech is a New York-based, privately held AI-driven drug discovery company founded in 2018. It applies biology-driven artificial intelligence to redesign early-stage drug discovery workflows for pharmaceutical and biotechnology partners, operating with a small technical team of 11–50 employees.
- Company typePrivate
- Founded2018
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
OneThree Biotech firmographics
Firmographics- Name
- OneThree Biotech
- Website
- https://onethree.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OneThree Biotech is a New York-based, privately held AI-driven drug discovery company founded in 2018. It applies biology-driven artificial intelligence to redesign early-stage drug discovery workflows for pharmaceutical and biotechnology partners, operating with a small technical team of 11–50 employees.
- Ownership category
- akta.pro rank
OneThree Biotech industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where OneThree Biotech is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
OneThree Biotech business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
OneThree Biotech product offering
Product offeringCore offering
OneThree Biotech redesigns drug discovery by applying biology-driven artificial intelligence to identify and validate novel therapeutic targets and drug candidates. The company builds computational biology and machine learning models that leverage biological data to accelerate early-stage drug discovery for pharmaceutical and biotechnology partners.
Differentiator
Problem solved
Functional benefit
Products and services
- OneThree Biotech AI Drug Discovery Platform A biology-driven artificial intelligence platform that identifies and validates novel therapeutic targets and drug candidates for pharmaceutical and biotechnology partners engaged in early-stage drug discovery.
Companies that use OneThree Biotech
Customer profileIdeal customer profiles1 record
OneThree Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OneThree Biotech competitors and assessment
Company assessmentDirect peers
- Exscientia: Exscientia builds AI-designed drug candidates and has signed multi-asset collaborations with major pharma, comparable to what an AI-discovery startup like OneThree aspires to grow into.
- XtalPi: XtalPi combines AI, physics-based modeling, and lab automation for drug discovery, sharing the AI-discovery-for-pharma business model that OneThree is pursuing.
- Cyclica: Cyclica uses AI and proteome-wide screening to support drug discovery and polypharmacology, comparable to OneThree as a smaller AI-native platform targeting pharma partnerships.
- Atomwise: Atomwise uses AI for small-molecule drug discovery, including target identification and hit optimization. It is directly comparable as an AI-native platform pitching pharma collaborations in the same buyer pool as OneThree.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover and develop drugs at scale, overlapping strongly with OneThree's biology-driven AI approach for target identification.
- Insitro: Insitro applies machine learning to biological data to predict which drugs will be effective, closely matching OneThree's biology-driven AI drug discovery thesis. Both target partnerships with large pharma using ML-augmented target identification and validation.
- BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs for drug discovery and target identification, operating in the same biology-first AI-for-drug-discovery category as OneThree.
Broad incumbents
- Schrödinger: Schrödinger offers a broad computational chemistry and biology platform widely used in drug discovery programs, providing overlapping AI/ML-driven molecular design capabilities and serving the same pharma R&D customer base.
- Isomorphic Labs: Alphabet's Isomorphic Labs applies AI to drug discovery, sharing the AI-augmented pharma-partnership business model though operating at vastly greater scale and capital intensity than OneThree.
Emerging players
- BPGbio: BPGbio (formerly Berg Pharma) uses AI-driven biology for drug discovery and target identification, overlapping with OneThree's biology-driven AI for pharma R&D use cases.
Market position
Customer concentration
OneThree Biotech social profiles
Digital presenceOneThree Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
OneThree Biotech leadership team
Management profileNumber of profiles
Profiles4 records
OneThree Biotech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OneThree Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OneThree Biotech
What does OneThree Biotech do?
OneThree Biotech redesigns drug discovery by applying biology-driven artificial intelligence to identify and validate novel therapeutic targets and drug candidates. The company builds computational biology and machine learning models that leverage biological data to accelerate early-stage drug discovery for pharmaceutical and biotechnology partners.
When was OneThree Biotech founded?
OneThree Biotech was founded in 2018. It employs 11 to 50 people.
Where is OneThree Biotech based?
OneThree Biotech is headquartered in New York, United States, in the North America region.
Who are OneThree Biotech's main competitors?
Direct peers on record are Exscientia, XtalPi, Cyclica, Atomwise, Recursion Pharmaceuticals, Insitro and BenevolentAI. Broad incumbents are Schrödinger and Isomorphic Labs. BPGbio is listed as an emerging player.
Does OneThree Biotech have an API?
No public API is recorded for OneThree Biotech.
What industry is OneThree Biotech in?
OneThree Biotech's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.